RxDoctor Payments Data

Fred Galluccio, MD

Family Medicine · Newport Beach, CANPI 1104934397

Payments from drug & device makers

$915in general payments, 2019–2025

Across 33 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$278
  • Amarin Pharma, Inc.$130
  • Inari Medical, Inc.$67
  • Merck$62
  • Novartis$57
  • Sanofi Pasteur Inc.$57
  • plus $265 from 11 others

What the payments were for

  • Food & beverage$90999%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$915 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$130,138
Medicare patients
111
Services billed
1,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate37$37,542
TrulicityDulaglutide12$25,519
Rosuvastatin Calcium414$7,515
Ezetimibe241$6,394
Colesevelam Hcl27$5,476
PaxlovidNirmatrelvir/Ritonavir15$2,858
Atorvastatin Calcium264$2,321
Levothyroxine Sodium175$2,288
Olmesartan Medoxomil25$2,132
Wixela InhubFluticasone Propion/Salmeterol20$1,922
Gabapentin50$1,201
Famotidine59$1,032
Lisinopril195$994
Metoprolol Succinate49$967
Tamsulosin Hcl60$897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$62$37,54237 claims
Lilly USA, LLCTrulicity$15$25,51912 claims
PfizerPaxlovid$26$2,85815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →